(Q43813968)

27 November 2017

Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis (English)

1 reference

27 November 2017

0 references

1 reference

Hussien Y

1

1 reference

27 November 2017

Sanna A

2

1 reference

27 November 2017

Söderström M

3

1 reference

27 November 2017

Link H

4

1 reference

27 November 2017

Huang YM

5

1 reference

27 November 2017

1 December 2001

1 reference

Journal of Neuroimmunology

27 November 2017

1 reference

27 November 2017

121

1 reference

27 November 2017

1-2

1 reference

27 November 2017

102-110

1 reference

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

IFN-beta interferes with the differentiation of dendritic cells from peripheral blood mononuclear cells: selective inhibition of CD40-dependent interleukin-12 secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Monocyte-derived dendritic cells: a potential target for therapy in multiple sclerosis (MS)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

IL-10 converts human dendritic cells into macrophage-like cells with increased antibacterial activity against virulent Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Mechanisms of immunomodulation by glatiramer acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

The ups and downs of multiple sclerosis therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Interferon-beta induces the development of type 2 dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Dendritic cells derived from patients with multiple sclerosis show high CD1a and low CD86 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Interferon beta in multiple sclerosis: is IL-12 suppression the key?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Immunomodulatory effects of interferon beta-1a in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Mechanisms of action of glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

The CD1 family of lipid antigen-presenting molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Reciprocal control of T helper cell and dendritic cell differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Proliferating dendritic cell progenitors in human blood

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

A filarial nematode-secreted product signals dendritic cells to acquire a phenotype that drives development of Th2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900432-5

7 January 2021

10.1016/S0165-5728(01)00432-5

Identifiers

DOI

1 reference

27 November 2017

1 reference